DOSAGE INDEX / SINGLE
GHRP-6
Research, reported schedules and supply planning.
Examine GHRP-6 human hormone and sleep studies, pharmacokinetics, metabolic findings, animal gut research and safety limits.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 100–300 micrograms per administration, totaling 300–900 micrograms daily
- Frequency
- Three times daily
- Cycle / observation period
- 8–12 weeks
- Route / research model
- Subcutaneous
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 2 mg | Enter a total |
| 5 mg | Enter a total |
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- The pharmacokinetic study included nine healthy men and three intravenous exposure levels. It estimated an average distribution half-life of 7.6 minutes and elimination half-life of 2.5 hours. The investigators also observed atypical concentration spikes in four participants. [1]
- A 1995 placebo comparison in healthy men examined repeated intravenous GHRP-6 administration during overnight monitoring. GH, ACTH and cortisol increased. Stage 2 sleep increased, while slow-wave sleep and other reported sleep-EEG measures did not change. [3]
- A human stimulation study included 25 adults and 12 prepubertal children. It found no GH-response differences between the studied age and sex groups under the tested conditions. Some adrenergic interventions altered responses while others did not. [4]
- FDA's safety discussion identifies limited information for GHRP-6 and raises concerns about immunogenicity, aggregation and peptide impurities. It also notes possible effects on cortisol and blood glucose through reduced insulin sensitivity. [7]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 78 entries mapped from 3 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original human pharmacokinetic study
- Original human antagonist study
- Original sleep and hormone study
- Original age, sex and adrenergic study
- Original oral stimulation study
- Original metabolic study
- FDA GHRP-6 safety discussion
- Original mouse transit study
- European Journal of Endocrinology (1997)Further reading · Listed in reference bibliography.
- Clinical Medicine Insights: Cardiology (2017)Further reading · Listed in reference bibliography.
- WikipediaFurther reading · Listed in reference bibliography.
- Sexual Medicine Reviews (2018)Further reading · Listed in reference bibliography.
- CDC (2024)General guidance · Listed in reference bibliography.
- CDC (2024)General guidance · Listed in reference bibliography.
- International Wound Journal (2018)Further reading · Listed in reference bibliography.
- CDC (2024)General guidance · Listed in reference bibliography.
- CDC (2024)General guidance · Listed in reference bibliography.
- Clinical Diabetes (2019)Further reading · Listed in reference bibliography.
- Kok et al., 1999, PMID 10206449 - Participants with NIDDM and controls received GHRP-6 90 mcg IV on a study occasion.Further reading · Listed in reference bibliography.
- Ghigo et al., 1994, PMID 7952160 - Seven elderly women received oral GHRP-6 300 mcg/kg before and after four days of twice-daily treatment.Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.